Silent plight
Why a new approach is needed for primary biliary cholangitis trials
Read More
Tag: PBC
End of the line for Genfit’s experimental NASH drug
Development of elafibranor will be discontinued for NASH, with the company now focusing on its future as a treatment for PBC
Read More
FDA warning on Intercept’s Ocaliva after patient deaths
US regulators have issued a safety communication warning of the risk for serious liver injury and death from incorrect dosing of Intercept Pharmaceuticals’ Ocaliva in patients with primary biliary cholangitis.
Read More
Ocalvia gets NHS green light for rare chronic liver disease
Intercept’s Ocaliva has been issued a final green light for use by the NHS to treat the rare chronic liver disease primary biliary cholangitis (PBC), which affects around one in 1,000 women over the age of 40 but is still the leading cause of liver transplantation in adult women in the UK.
Read More
NICE backs new treatment for chronic liver disease
Intercept’s Ocaliva is being backed by the National Institute for Health and Care Excellence for routine NHS commissioning as a treatment for people with the chronic liver disease primary biliary cholangitis (PBC).
Read More
EU approves new therapy for rare liver condition PBC
The European Commission has cleared Intercept’s Ocaliva for the treatment of primary biliary cholangitis (PBC), giving patients the potential to access the first new therapy for the condition in nearly 20 years.
Read More
- Acoramidis approved for heart condition treatment
- Genomics study launches to optimise childhood cancer care in Ireland
- UCL researchers launch congenital muscular dystrophy research programme
- Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
- FDA approves Click’s digital therapeutic for episodic migraine
